Karyopharm Therapeutics Inc (KPTI)

$0.89

+0.01

(+0.73%)▲

Market is closed - opens 7 PM, 07 Oct 2024

Performance

  • $0.84
    $0.91
    $0.89
    downward going graph

    5.6%

    Downside

    Day's Volatility :7.45%

    Upside

    1.96%

    downward going graph
  • $0.62
    $1.95
    $0.89
    downward going graph

    30.63%

    Downside

    52 Weeks Volatility :68.34%

    Upside

    54.36%

    downward going graph

Returns

PeriodKaryopharm Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
7.61%
5.7%
0.0%
6 Months
-33.76%
6.7%
0.0%
1 Year
-29.52%
18.4%
0.0%
3 Years
-84.62%
20.8%
-20.2%

Highlights

Market Capitalization
109.8M
Book Value
- $1.06
Earnings Per Share (EPS)
-1.14
PEG Ratio
-0.15
Wall Street Target Price
4.36
Profit Margin
-61.72%
Operating Margin TTM
-65.72%
Return On Assets TTM
-31.98%
Return On Equity TTM
-891.05%
Revenue TTM
145.7M
Revenue Per Share TTM
1.25
Quarterly Revenue Growth YOY
13.900000000000002%
Gross Profit TTM
151.9M
EBITDA
-130.6M
Diluted Eps TTM
-1.14
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.66
EPS Estimate Next Year
-0.67
EPS Estimate Current Quarter
-0.3
EPS Estimate Next Quarter
-0.29

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Karyopharm Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
2
2
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 389.89%

Current $0.89
Target $4.36

Company Financials

FY18Y/Y Change
Revenue
30.3M
↑ 1790.09%
Net Income
-178.4M
↑ 38.32%
Net Profit Margin
-588.1%
↑ 7448.29%
FY19Y/Y Change
Revenue
40.9M
↑ 34.8%
Net Income
-199.6M
↑ 11.87%
Net Profit Margin
-488.08%
↑ 100.02%
FY20Y/Y Change
Revenue
108.1M
↑ 164.31%
Net Income
-196.3M
↓ 1.66%
Net Profit Margin
-181.59%
↑ 306.49%
FY21Y/Y Change
Revenue
209.8M
↑ 94.12%
Net Income
-124.1M
↓ 36.78%
Net Profit Margin
-59.14%
↑ 122.45%
FY22Y/Y Change
Revenue
157.1M
↓ 25.14%
Net Income
-165.3M
↑ 33.2%
Net Profit Margin
-105.23%
↓ 46.09%
FY23Y/Y Change
Revenue
146.0M
↓ 7.03%
Net Income
-143.1M
↓ 13.43%
Net Profit Margin
-97.99%
↑ 7.24%
Q1 FY23Q/Q Change
Revenue
38.7M
↑ 15.24%
Net Income
-34.1M
↓ 11.37%
Net Profit Margin
-88.19%
↑ 26.48%
Q2 FY23Q/Q Change
Revenue
37.6M
↓ 2.89%
Net Income
-32.6M
↓ 4.38%
Net Profit Margin
-86.83%
↑ 1.36%
Q3 FY23Q/Q Change
Revenue
36.0M
↓ 4.18%
Net Income
-34.5M
↑ 5.75%
Net Profit Margin
-95.83%
↓ 9.0%
Q4 FY23Q/Q Change
Revenue
33.7M
↓ 6.28%
Net Income
-41.8M
↑ 21.25%
Net Profit Margin
-123.97%
↓ 28.14%
Q1 FY24Q/Q Change
Revenue
33.1M
↓ 1.84%
Net Income
-37.4M
↓ 10.7%
Net Profit Margin
-112.79%
↑ 11.18%
Q2 FY24Q/Q Change
Revenue
42.8M
↑ 29.16%
Net Income
23.8M
↓ 163.68%
Net Profit Margin
55.61%
↑ 168.4%
FY18Y/Y Change
Total Assets
341.2M
↑ 89.24%
Total Liabilities
158.0M
↑ 210.88%
FY19Y/Y Change
Total Assets
295.0M
↓ 13.55%
Total Liabilities
245.2M
↑ 55.16%
FY20Y/Y Change
Total Assets
313.1M
↑ 6.13%
Total Liabilities
262.5M
↑ 7.06%
FY21Y/Y Change
Total Assets
305.3M
↓ 2.47%
Total Liabilities
385.0M
↑ 46.66%
FY22Y/Y Change
Total Assets
358.2M
↑ 17.32%
Total Liabilities
374.8M
↓ 2.64%
FY23Y/Y Change
Total Assets
240.4M
↓ 32.87%
Total Liabilities
376.6M
↑ 0.48%
Q1 FY23Q/Q Change
Total Assets
325.8M
↓ 9.04%
Total Liabilities
371.0M
↓ 1.03%
Q2 FY23Q/Q Change
Total Assets
297.8M
↓ 8.59%
Total Liabilities
369.1M
↓ 0.51%
Q3 FY23Q/Q Change
Total Assets
270.0M
↓ 9.36%
Total Liabilities
370.4M
↑ 0.35%
Q4 FY23Q/Q Change
Total Assets
240.4M
↓ 10.94%
Total Liabilities
376.6M
↑ 1.7%
Q1 FY24Q/Q Change
Total Assets
204.5M
↓ 14.96%
Total Liabilities
373.4M
↓ 0.86%
Q2 FY24Q/Q Change
Total Assets
214.0M
↑ 4.66%
Total Liabilities
346.1M
↓ 7.31%
FY18Y/Y Change
Operating Cash Flow
-159.1M
↑ 115.85%
Investing Cash Flow
-107.7M
↓ 729.32%
Financing Cash Flow
316.1M
↑ 317.34%
FY19Y/Y Change
Operating Cash Flow
-190.8M
↑ 19.93%
Investing Cash Flow
78.5M
↓ 172.87%
Financing Cash Flow
124.3M
↓ 60.68%
FY20Y/Y Change
Operating Cash Flow
-160.2M
↓ 16.03%
Investing Cash Flow
-53.7M
↓ 168.43%
Financing Cash Flow
172.1M
↑ 38.44%
FY21Y/Y Change
Operating Cash Flow
-107.1M
↓ 33.15%
Investing Cash Flow
141.8M
↓ 364.21%
Financing Cash Flow
73.6M
↓ 57.2%
FY22Y/Y Change
Operating Cash Flow
-149.6M
↑ 39.62%
Investing Cash Flow
-104.3M
↓ 173.5%
Financing Cash Flow
193.7M
↑ 163.06%
Q1 FY23Q/Q Change
Operating Cash Flow
-18.9M
↓ 29.55%
Investing Cash Flow
-32.4M
↓ 50.4%
Financing Cash Flow
0.0
↓ 100.0%

Technicals Summary

Sell

Neutral

Buy

Karyopharm Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
23.61%
-33.76%
-29.52%
-84.62%
-91.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-13.97%
8.28%
24.49%
82.67%
258.6%
Novo Nordisk A/s
Novo Nordisk A/s
-14.46%
-7.16%
29.25%
137.43%
348.48%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
6.47%
77.93%
59.32%
38.21%
249.95%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.23%
12.26%
28.5%
155.67%
163.05%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
NA
NA
-0.15
-0.66
-8.91
-0.32
NA
-1.06
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.55
27.55
1.42
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
38.7
38.7
1.75
3.41
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.55
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc
Buy
$109.8M
-91.61%
NA
-61.72%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$114.7B
258.6%
27.55
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$518.0B
348.48%
38.7
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.9B
249.95%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$119.3B
163.05%
32.84
-4.74%

Insights on Karyopharm Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 33.12M → 42.78M (in $), with an average increase of 22.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -41.83M → 23.79M (in $), with an average increase of 134.5% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.3% return, outperforming this stock by 88.8%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.2% return, outperforming this stock by 122.8%

Institutional Holdings

  • Vanguard Group Inc

    6.14%

  • Palo Alto Investors, LLC

    4.09%

  • Eversept Partners, LLC

    4.00%

  • Adage Capital Partners Gp LLC

    3.46%

  • BlackRock Inc

    3.34%

  • Citadel Advisors Llc

    2.49%

Company Information

karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com

Organization
Karyopharm Therapeutics Inc
Employees
325
CEO
Mr. Richard A. Paulson M.B.A.
Industry
Health Technology

Discover More

FAQs